GlycoMimetics to Receive European Patent for GMI-1271
July 06 2017 - 9:00AM
Business Wire
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the
European Patent Office has issued an “intention to grant” letter
for European Patent Application Number EP12813711.1, titled
“E-Selectin Antagonist Compounds, Compositions, and Methods of
Use.” This patent is part of GlycoMimetics’ expanding
patent portfolio covering the drug candidate GMI-1271 and its uses
in a variety of indications, including various cancers. The U.S.
Patent and Trademark Office has already issued a
patent covering GMI-1271. GlycoMimetics has ongoing efforts to
secure additional U.S. and foreign patents. With the issuance of
patents in the U.S. and Europe, GlycoMimetics will have claims
directed at GMI-1271 extending at least until 2032.
“The European Patent Office’s issuance of patent rights covering
GMI-1271 underscores the progress we’ve made in protecting our
intellectual property and innovative pipeline,” said Rachel
King, Chief Executive Officer, GlycoMimetics. “The release of
promising new clinical data in both the newly diagnosed and
relapsed/refractory acute myeloid leukemia (AML) patient
populations from our ongoing study during the 2017 ASCO and EHA
meetings, the U.S. Food and Drug Administration’s (FDA)
Breakthrough Therapy Designation, and our enhanced patent position
provide a strong foundation for defining a pivotal registration
program and commercialization strategy for GMI-1271.”
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company
focused on cancer and sickle cell disease. GlycoMimetics’ most
advanced drug candidate, rivipansel, a pan-selectin antagonist, is
being developed for the treatment of vaso-occlusive crisis in
sickle cell disease and is being evaluated in a Phase 3 clinical
trial being conducted by its strategic collaborator,
Pfizer. GlycoMimetics' wholly-owned drug candidate,
GMI-1271, an E-selectin antagonist, is being evaluated in an
ongoing Phase 1/2 clinical trial as a potential treatment for AML
and in a Phase 1 clinical trial in multiple myeloma. The U.S.
FDA recently granted GMI-1271 Breakthrough Therapy designation
for treatment of adult AML patients with relapsed/refractory
disease. GlycoMimetics has also recently initiated a clinical
trial with a third drug candidate, GMI-1359, a combined CXCR4 and
E-selectin antagonist. GlycoMimetics is located
in Rockville, MD in the BioHealth Capital Region.
Learn more at www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidate GMI-1271. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including the
availability and timing of data from ongoing clinical trials, the
uncertainties inherent in the completion of ongoing clinical trials
and the initiation of future clinical trials, whether interim
results from a clinical trial will be predictive of the final
results of the trial or results of early clinical trials will be
indicative of the results of future trials, expectations for
regulatory approvals, availability of funding sufficient for
GlycoMimetics' foreseeable and unforeseeable operating expenses and
capital expenditure requirements, other matters that could affect
the availability or commercial potential of GlycoMimetics' drug
candidates and other factors discussed in the "Risk Factors"
section of GlycoMimetics' Annual Report on Form 10-K that was filed
with the U.S. Securities and Exchange
Commission on March 1, 2017, and other
filings GlycoMimetics makes with the Securities and
Exchange Commission from time to time. In addition, the
forward-looking statements included in this press release represent
GlycoMimetics' views as of the date
hereof. GlycoMimetics anticipates that subsequent events
and developments may cause its views to change. However,
while GlycoMimetics may elect to update these
forward-looking statements at some point in the
future, GlycoMimetics specifically disclaims any
obligation to do so, except as may be required by law. These
forward-looking statements should not be relied upon as
representing GlycoMimetics' views as of any date subsequent to the
date hereof.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170706005056/en/
GlycoMimetics, Inc.Investor Contact:Shari Annes,
650-888-0902sannes@annesassociates.comorMedia Contact:Jamie
Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Aug 2024 to Sep 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Sep 2023 to Sep 2024